XTX Topco Ltd Invests $129,000 in Alumis Inc. (NASDAQ:ALMS)

XTX Topco Ltd acquired a new stake in shares of Alumis Inc. (NASDAQ:ALMS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 16,446 shares of the company’s stock, valued at approximately $129,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mariner LLC bought a new position in Alumis in the 4th quarter worth approximately $142,000. Barclays PLC boosted its position in shares of Alumis by 33.9% during the fourth quarter. Barclays PLC now owns 24,581 shares of the company’s stock worth $193,000 after acquiring an additional 6,221 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after acquiring an additional 3,823 shares during the last quarter. Geode Capital Management LLC lifted its stake in Alumis by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 315,571 shares of the company’s stock worth $2,481,000 after purchasing an additional 9,891 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Alumis during the 4th quarter valued at about $1,606,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Oppenheimer initiated coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Finally, HC Wainwright reduced their price target on shares of Alumis from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, April 22nd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.86.

Insider Activity

In other Alumis news, Director Alan Colowick acquired 16,104 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were bought at an average price of $6.97 per share, with a total value of $112,244.88. Following the transaction, the director now directly owns 16,104 shares of the company’s stock, valued at $112,244.88. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Martin Babler bought 15,650 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were acquired at an average price of $6.44 per share, with a total value of $100,786.00. Following the completion of the transaction, the chief executive officer now owns 106,454 shares of the company’s stock, valued at approximately $685,563.76. The trade was a 17.23 % increase in their position. The disclosure for this purchase can be found here.

Alumis Trading Up 5.1 %

Shares of NASDAQ:ALMS opened at $4.33 on Wednesday. Alumis Inc. has a 12 month low of $3.18 and a 12 month high of $13.53. The firm’s 50-day moving average is $5.47 and its 200 day moving average is $7.58.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.